ARAMIS Patient Summary
PHEN Clinical Trials Rally
Patients should consider the ARAMIS trial if hormone therapy treatments, such as Lupron, no longer keep their PSA from rising but their doctor has not detected any prostate cancer spread to other parts of the body. This is called high-risk non-metastatic castration-resistant prostate cancer.
Patients who participate in the ARAMIS trial are randomly (by chance) assigned to receive the experimental drug BAY1841788 (ODM-201) or a placebo to determine if the experimental drug is effective in keeping prostate cancer from progressing. Neither the researchers nor the participants can choose or know who is assigned to which group.
Possible patient benefits include slowing the spread (progression) of prostate cancer to other parts of the body and prolonging life.
If you are interested in this trial you can take these actions:
ARAMIS Sponsor: Bayer; Contact: 646-776-7532 or 844-229-3710 (toll free), email: Bayer@emergingmed.com